Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Response to Arguments
The objections to the Drawings are withdrawn in view of the amendment filed on 9/22/2026.
The objections to the specification is withdrawn in view of the amendment filed on 9/22/2026.
Applicant’s arguments in view of the claim amendments filed on 9/26/2026, with respect to the 35 U.S.C. §112 rejections have been fully considered and are persuasive. The 35 U.S.C. §112 rejections have been withdrawn.
Applicant’s arguments in view of the claim amendments filed on 9/22/2026, with respect to the 35 U.S.C. §101 rejections have been fully considered and are persuasive. The 35 U.S.C. §101 rejections have been withdrawn.
The non-statutory double patenting rejections have been withdrawn based on the terminal disclaimer filed and approved on 10/23/2026.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 1-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claim 13 recites the limitation "a representation of a future causation score computed based on the future dataset associated with the future year." There is insufficient antecedent basis for the limitation "the future dataset" in the claim. No future dataset is introduced in claim 13 before this recitation; by contrast, the parallel limitation of claim 1 recites "a future dataset." Claim 13 also recites "simulating the future publication dataset by sampling a weighted mixture of the plurality of time-constrained publication distributions." There is insufficient antecedent basis for the limitation "the future publication dataset" in the claim, because the term is first recited with the definite article; the parallel limitation of claim 1 recites "simulating a future publication dataset." Both defects were introduced by the amendment filed September 22, 2026. The missing antecedents render claim 13 indefinite, rather than merely informal, because the scope of the limitation is not reasonably ascertainable from context: as explained in the following paragraph, claim 13 refers to the dataset from which the future causation score is computed by two different names, so a person of ordinary skill cannot determine whether "the future dataset" and "the future publication dataset" denote one dataset or two, and cannot supply the missing antecedents by inference. See MPEP 2173.05(e) (citing Ex parte Porter, 25 USPQ2d 1144 (Bd. Pat. App. & Inter. 1992), and Bose Corp. v. JBL, Inc., 274 F.3d 1354 (Fed. Cir. 2001)). For purposes of examination, "the future dataset" and "the future publication dataset" in claim 13 are each interpreted under BRI as the simulated future publication dataset produced by the recited sampling step, because the specification at ¶[0030]-[0033] describes a single future publication dataset, drawn from the weighted mixture of the publication distributions, from which the future causation score is computed. See MPEP 2173.05(e).
Claims 1 and 13 are indefinite because the limitation directed to the future causation score recites the dataset from which that score is computed under two different names. Claim 1 recites "a representation of a future causation score computed based on a future dataset associated with the future year, including:" and then, within the steps that define the computation, "simulating a future publication dataset" and "computing the future causation score based on the future publication dataset." Claim 13 recites the same structure with "the future dataset" and "the future publication dataset." The claims thus introduce both "a future dataset" and "a future publication dataset" and attribute the computation of the same score to each. The limitation is amenable to two plausible constructions. Under the first, the "future dataset" and the "future publication dataset" are a single simulated dataset recited under two names. Under the second, the "future dataset associated with the future year" is a dataset derived from one or more simulated future publication datasets, for example the set of future causation scores, or the aggregate of many simulated datasets, that the specification describes at ¶[0033] ("1000 future publication datasets may be sampled ... to obtain 1000 future causation scores" that are "aggregated and analyzed to determine the causation score distribution"), with the "future publication dataset" an intermediate from which the "future dataset" is obtained. The claims do not state which is intended, do not define the "future dataset," and do not state how it relates to the "future publication dataset." The specification uses only the term "future publication dataset" (¶[0030]-[0033]) and describes no separate "future dataset," so it does not resolve the question. Where a claim is amenable to two or more plausible constructions, the Office is justified in requiring the applicant to more precisely define the metes and bounds of the claimed invention. Ex parte Miyazaki, 89 USPQ2d 1207, 1211 (BPAI 2008) (precedential); MPEP 2173.02; see Nautilus, Inc. v. Biosig Instruments, Inc., 572 U.S. 898 (2014). For purposes of examination, "a future dataset associated with the future year" (claim 1), "the future dataset associated with the future year" (claim 13), and "the future publication dataset" (claims 1 and 13) are interpreted under BRI as the same dataset, namely the simulated future publication dataset produced by the sampling step.
Claims 1 and 13 recite "wherein the future publication count is predicted for the future year as a random walk from a short-term average publication rate." The term "short-term" in claims 1 and 13 is a relative term which renders the claim indefinite. The term "short-term" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The claims do not state the period over which the average publication rate is taken, or what "short" is relative to. The specification at paragraph [0034] repeats the phrase ("a random walk from the short term average publication rate") and gives one example in which "the history of publication counts from year 1 to year n can be analyzed to calculate the exponential moving average"; that example uses the entire publication history, so it supplies no horizon that distinguishes a short-term average from any other average. A term of degree is definite only if the specification provides some standard, that is, objective boundaries, for measuring it. Interval Licensing LLC v. AOL, Inc., 766 F.3d 1364, 1370-71 (Fed. Cir. 2014); MPEP 2173.05(b). "Short-term" is not a term of art with a fixed meaning in bibliometrics or time-series analysis; it has meaning only relative to some longer term, and the claims identify none. The specification's example does not supply the missing boundary: an exponential moving average computed over the whole publication history is not "short-term" by reference to any window, so the example shows that the applicant's own usage is untethered to a time horizon rather than tethered to one. Applicant's Remarks filed September 22, 2026 (pages 13-14) describe the random walk but do not define the term. A person of ordinary skill therefore cannot determine whether an average over the preceding year, the preceding five years, or the whole recency-weighted history is within the claim. For purposes of examination, "a short-term average publication rate" is interpreted under BRI to encompass any average of the publication rate computed over a recent period or with recency weighting.
Claim 10 recites "wherein respective proximity categorizations categorize each article in the first dataset as at least one of a human study, an animal study, and an in vitro study." The phrase "at least one of a human study, an animal study, and an in vitro study" is ambiguous. The phrase is amenable to two plausible constructions. Under the default construction of "at least one of A, B, and C" adopted in SuperGuide Corp. v. DirecTV Enterprises, Inc., 358 F.3d 870, 886 (Fed. Cir. 2004), and applied by the Board in Ex parte Jung, Appeal No. 2016-008290 (PTAB Mar. 22, 2017) (construing "at least one of A and B" conjunctively absent an indication to the contrary), the limitation requires each article to be categorized as at least one human study and at least one animal study and at least one in vitro study, which is not a categorization and contradicts the specification, which describes "a simple categorization of each study as either human, animal, or in vitro" (¶[0019]). Under the disjunctive construction that the specification supports, the limitation requires categorization into one or more of the three. Because the claim language supports the conjunctive reading while the specification supports only the disjunctive reading, the claim is amenable to two plausible constructions, and the Office is justified in requiring the applicant to define the limitation more precisely. Ex parte Miyazaki, 89 USPQ2d 1207, 1211 (BPAI 2008) (precedential); MPEP 2173.02; MPEP 2173.05(h). For purposes of examination, the limitation is interpreted under BRI disjunctively, so that each article is categorized as a human study, an animal study, an in vitro study, or any combination of these.
Claims 2-12 depend directly or indirectly from claim 1, and claims 14-20 depend directly or indirectly from claim 13. Each incorporates the indefinite limitations of the claim from which it depends and is rejected for the same reasons.
Appropriate correction is required.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALAN CHEN whose telephone number is (571)272-4143. The examiner can normally be reached M-F 10-7.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kamran Afshar can be reached at (571) 272-7796. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ALAN CHEN/Primary Examiner, Art Unit 2125